A case of metastatic colon cancer effectively treated by XELOX and IRIS

Toshihiro Nishizawa; Satoshi Kinoshita; Takashi Sakuno; Yoichi Fujiyama; Miho Kikuchi; Hiroshi Kaneko; Hidekazu Suzuki; Masahiko Takahashi

A case of metastatic colon cancer effectively treated by XELOX and IRIS

Toshihiro Nishizawa, Satoshi Kinoshita, Takashi Sakuno, Yoichi Fujiyama, Miho Kikuchi, Hiroshi Kaneko, Hidekazu Suzuki, Masahiko Takahashi

Research output: Contribution to journal › Article › peer-review

Abstract

The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin (XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade 3 hand-foot syndrome and peripheral neuropathy. Irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) and (IRIS)+bevacizumab were continued as second-line therapy, and her status was maintained as stable disease. XELOX and IRIS regimens do not require catheter placement and long infusion process, providing a great advantage to patients.

Original language	English
Pages (from-to)	807-809
Number of pages	3
Journal	Japanese Journal of Cancer and Chemotherapy
Volume	40
Issue number	6
Publication status	Published - 2013 Jun
Externally published	Yes

Keywords

Colon cancer
IRIS
XELOX

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{99ba051a448347098cd520b68a186efa,

title = "A case of metastatic colon cancer effectively treated by XELOX and IRIS",

abstract = "The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin (XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade 3 hand-foot syndrome and peripheral neuropathy. Irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) and (IRIS)+bevacizumab were continued as second-line therapy, and her status was maintained as stable disease. XELOX and IRIS regimens do not require catheter placement and long infusion process, providing a great advantage to patients.",

keywords = "Colon cancer, IRIS, XELOX",

author = "Toshihiro Nishizawa and Satoshi Kinoshita and Takashi Sakuno and Yoichi Fujiyama and Miho Kikuchi and Hiroshi Kaneko and Hidekazu Suzuki and Masahiko Takahashi",

year = "2013",

month = jun,

language = "English",

volume = "40",

pages = "807--809",

journal = "Japanese Journal of Cancer and Chemotherapy",

issn = "0385-0684",

publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",

number = "6",

}

TY - JOUR

T1 - A case of metastatic colon cancer effectively treated by XELOX and IRIS

AU - Nishizawa, Toshihiro

AU - Kinoshita, Satoshi

AU - Sakuno, Takashi

AU - Fujiyama, Yoichi

AU - Kikuchi, Miho

AU - Kaneko, Hiroshi

AU - Suzuki, Hidekazu

AU - Takahashi, Masahiko

PY - 2013/6

Y1 - 2013/6

N2 - The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin (XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade 3 hand-foot syndrome and peripheral neuropathy. Irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) and (IRIS)+bevacizumab were continued as second-line therapy, and her status was maintained as stable disease. XELOX and IRIS regimens do not require catheter placement and long infusion process, providing a great advantage to patients.

AB - The patient was a 78-year-old woman who suffered from right upper quadrant pain. She was diagnosed as colon cancer with hepatic metastasis. Initial chemotherapy using capecitabine plus oxaliplatin (XELOX)+bevacizumab achieved partial response. After 12 months, XELOX was discontinued due to Grade 3 hand-foot syndrome and peripheral neuropathy. Irinotecan plus oral S-1 (a combination of tegafur, 5-chloro-2, 4-dihydroxypyridine, and potassium oxonate) and (IRIS)+bevacizumab were continued as second-line therapy, and her status was maintained as stable disease. XELOX and IRIS regimens do not require catheter placement and long infusion process, providing a great advantage to patients.

KW - Colon cancer

KW - IRIS

KW - XELOX

UR - http://www.scopus.com/inward/record.url?scp=84882794680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882794680&partnerID=8YFLogxK

M3 - Article

C2 - 23863664

AN - SCOPUS:84882794680

SN - 0385-0684

VL - 40

SP - 807

EP - 809

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

IS - 6

ER -

A case of metastatic colon cancer effectively treated by XELOX and IRIS

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this